EGFR is a particularly promising molecular target of therapy, as EGFR inhibitors have been widely applied to a variety of solid tumors, such as lung cancer [13], [14], colorectal cancer [29], breast cancer [30], and even ESCC [31]. This evidence concerns the gene EGFR and breast carcinoma.